Allogene Therapeutics, Inc. (ALLO) — Stock Score Summary

Allogene Therapeutics, Inc. (ALLO) has a MoatMap StockRank of 29/100 based on Quality (29/100), Value (39/100), and Momentum (48/100) factor scores. The current signal is SELL. Allogene Therapeutics is a clinical-stage biotech focused on allogeneic CAR-T therapies. It lacks commercial products, has high cash burn, and does not align with our CDMO pricing power theme as it is not a third-party manufacturer.

Allogene Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic (off-the-shelf) CAR T cell therapies for cancer, aiming to provide a more scalable and accessible treatment option than autologous therapies. The company is a key innovator in the cellular immunotherapy space, leveraging its proprietary platform to advance multiple candidates for various hematologic malignancies and solid tumors, positioning itself to address a significant unmet medical need.

Key Financial Metrics

Price$1.82
Market Cap$777M
P/E (Forward)-2.65
Price/Book1.79
Return on Equity-52.3%
Return on Invested Capital-49.5%
Debt/Equity29.06
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-70M

Allogene Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Allogene Therapeutics, Inc.’s (ALLO) StockRank?
MoatMap’s StockRank for Allogene Therapeutics, Inc. (ALLO) is 29/100, with a Sell signal. It is a composite of Quality (29), Value (39), and Momentum (48) factor ranks across MoatMap’s 19,000+ stock universe.
Does Allogene Therapeutics, Inc. have an economic moat?
Allogene Therapeutics, Inc. (ALLO) has a Quality factor score of 29/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Allogene Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Allogene Therapeutics, Inc. (ALLO) is Sell, based on a StockRank of 29/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Allogene Therapeutics, Inc. in?
Allogene Therapeutics, Inc. (ALLO) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksALLO deep dive reportAI ChampionsHow we score stocksSense-check another stock